Antitumor effect of N-9-[2-(phosphonomethoxy) ethyl]-2,6-diaminopurine (PMEDAP) was studied in an in vivo model of s.c. transplanted Sprague-Dawley (SD/cub) rat T-cell lymphomas. Three individual SD/cub neoplasias (SD10/96, SD14/97, SD1/90) of different phenotypes were used. During the treatment, survival of the rats, increase of lymphoma mass, and DNA fragmentation detected by APO/BRDU kit, as well as Bcl2 and p53 protein expression, were followed. The study gives evidence of the positive therapeutic effect of PMEDAP in two of the three tested lymphomas, SD10/96 and SD14/97. Slowly growing SD1/90 lymphoma differs from the others in a uniform karyotype with trisomy of chromosome 11, CD4- immunophenotype, heterogeneous cellular morphology and constitutive expression of p53 protein found in some neoplastic cells. Thus, the diverse anticancer efficacy of PMEDAP treatment among SD/cub lymphomas could be associated with the different phenotypes of individual neoplasias.

• MeSH
• adenin analogy a deriváty   terapeutické užití   MeSH
• antitumorózní látky terapeutické užití   MeSH
• apoptóza účinky léků   MeSH
• imunohistochemie MeSH
• karyotypizace MeSH
• koncové značení zlomů DNA in situ MeSH
• krysa rodu Rattus MeSH
• lymfom T-buněčný farmakoterapie   genetika   patologie   MeSH
• mapování chromozomů MeSH
• nádorový supresorový protein p53 analýza   MeSH
• potkani Sprague-Dawley MeSH
• protoonkogenní proteiny c-bcl-2 analýza   MeSH
• trizomie MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine MeSH Prohlížeč
• adenin MeSH
• antitumorózní látky MeSH
• nádorový supresorový protein p53 MeSH
• protoonkogenní proteiny c-bcl-2 MeSH